Chronic morphine administration results in tolerance to delta opioid receptor-mediated antinociception.
Delta opioid receptor agonists produce only a moderate degree of antinociception, possibly reflecting the predominantly intracellular location of delta opioid receptor. However, recent studies suggest that short term morphine pretreatment can increase delta opioid receptor-mediated antinociception by promoting the translocation of delta opioid receptor to the cell surface. Even more striking sensitization has been reported after long term morphine pretreatment and withdrawal in locomotor tests. In the present study we therefore examined the effects of longer term morphine pretreatment and withdrawal on delta opioid receptor-mediated antinociception in the formalin test. Male adult rats were pretreated daily with morphine (10 mg/kg s.c.) or saline for 10 days, and were tested acutely with the delta opioid receptor agonist [D-Ala2,Glu4]-deltorphin (intrathecal) at 0, 7 and 14 days of withdrawal. Unexpectedly, chronic morphine pre-exposure resulted in tolerance to [D-Ala2,Glu4]-deltorphin-induced antinociception, and this occurred at 0 and 7 but not 14 days of morphine withdrawal. Morphine challenge at withdrawal day 7 confirmed the presence of tolerance to the antinociceptive effects of this drug. Chronic morphine pretreatment also resulted in tolerance to the locomotor stimulant effect of [D-Ala2,Glu4]-deltorphin (given i.c.v.), contrary to a previous report of sensitization. However, consistent with previous reports, short term (2 day) pretreatment with morphine did result in sensitization to [D-Ala2,Glu4]-deltorphin. Subsequent in vitro analysis, using [125I][D-Ala2,Glu4]-deltorphin or guanosine 5'(gamma-35S-thio) triphosphate autoradiography, did not reveal any changes in delta opioid receptor binding or function resulting from chronic morphine pretreatment. In conclusion, chronic morphine pretreatment caused tolerance to delta opioid receptor-mediated behavioral effects with no clear change at the receptor level.
Pradhan
A A A
AAA
Department of Pharmacology and Therapeutics, McGill University, 3655 Promenade Sir William Osler, Room 1325, Montreal, QC H3G 1Y6 Canada.
Siau
C
C
Department of Anesthesia, McGill University, Montreal, QC H3G 1Y6 Canada.
Constantin
A
A
Department of Pharmacology and Therapeutics, McGill University, 3655 Promenade Sir William Osler, Room 1325, Montreal, QC H3G 1Y6 Canada.
Clarke
P B S
PBS
Department of Pharmacology and Therapeutics, McGill University, 3655 Promenade Sir William Osler, Room 1325, Montreal, QC H3G 1Y6 Canada. Electronic address: paul.clarke@mcgill.ca.
D000700:Analgesics / Q000008:administration & dosage*; D000818:Animals; D001345:Autoradiography / Q000379:methods; D001522:Behavior, Animal / Q000187:drug effects; D001923:Brain Chemistry / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004347:Drug Interactions; D004361:Drug Tolerance / Q000502:physiology*; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000493:pharmacokinetics; D007456:Iodine Isotopes / Q000493:pharmacokinetics; D008297:Male; D009020:Morphine / Q000008:administration & dosage / Q000009:adverse effects*; D009043:Motor Activity / Q000187:drug effects; D009294:Narcotics / Q000008:administration & dosage / Q000009:adverse effects*; D009842:Oligopeptides / Q000494:pharmacology; D010147:Pain Measurement / Q000379:methods; D010759:Phosphorus Isotopes / Q000493:pharmacokinetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D017465:Receptors, Opioid, delta / Q000502:physiology*
D000700:Analgesics; D007456:Iodine Isotopes; D009294:Narcotics; D009842:Oligopeptides; D010759:Phosphorus Isotopes; D017465:Receptors, Opioid, delta; C060208:deltorphin I, Ala(2)-; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D009020:Morphine